维塞那肽作为二甲双胍附加疗法对 2 型糖尿病患者的疗效和安全性:一项随机、双盲、平行、安慰剂对照的 3 期研究

IF 7.6 1区 医学 Q1 HEALTH CARE SCIENCES & SERVICES The Lancet Regional Health: Western Pacific Pub Date : 2024-10-01 DOI:10.1016/j.lanwpc.2024.101197
Xiaoling Cai , Linong Ji , Mingxia Yuan , Jianhua Ma , Fang Bian , Sheli Li , Wuyan Pang , Shuang Yan , Huimin Zhou , Minghui Hou , Wenhui Li , Ying Jia , Li Liu , Ke Ding , Michael Xu
{"title":"维塞那肽作为二甲双胍附加疗法对 2 型糖尿病患者的疗效和安全性:一项随机、双盲、平行、安慰剂对照的 3 期研究","authors":"Xiaoling Cai ,&nbsp;Linong Ji ,&nbsp;Mingxia Yuan ,&nbsp;Jianhua Ma ,&nbsp;Fang Bian ,&nbsp;Sheli Li ,&nbsp;Wuyan Pang ,&nbsp;Shuang Yan ,&nbsp;Huimin Zhou ,&nbsp;Minghui Hou ,&nbsp;Wenhui Li ,&nbsp;Ying Jia ,&nbsp;Li Liu ,&nbsp;Ke Ding ,&nbsp;Michael Xu","doi":"10.1016/j.lanwpc.2024.101197","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Visepegenatide, a once-weekly glucagon-like peptide-1 receptor agonist injection, demonstrated effective glycaemic control and good tolerability without the requirement of dose titration in the two completed phase 2 studies. We aimed to evaluate the efficacy and safety of visepegenatide in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin monotherapy in this phase 3 clinical study.</div></div><div><h3>Methods</h3><div>This multicentre phase 3 clinical study included a 24-week, randomised, placebo-controlled, double-blind period followed by a 28-week open-label extended treatment period. Patients (N = 620) aged ≥18 and ≤75 years with glycated haemoglobin (HbA<sub>1c</sub>) ≥7.0% and ≤10.5% [≥53.0 and ≤91.27 mmol/mol], were randomized in a 1:1 ratio to receive visepegenatide 150-μg or placebo once-weekly subcutaneous injection during the double-blind period. Subsequently, the patients in the placebo group were switched to visepegenatide treatment (placebo→visepegenatide group), and the patients in the visepegenatide group continued the same treatment during the open-label extended treatment period. The primary endpoint was the change in HbA<sub>1c</sub> from baseline to week 24.</div></div><div><h3>Findings</h3><div>At week 24, the placebo-adjusted least squares mean (LSM) change of HbA<sub>1c</sub> was −0.57% (95% CI −0.71 to −0.43) with visepegenatide (p &lt; 0.001). The proportion of patients achieving HbA<sub>1c</sub> &lt; 7.0% and ≤6.5% [&lt;53 and ≤ 48 mmol/mol] was higher in the visepegenatide group versus the placebo group (115 [40.5%] <em>vs</em> 50 [17.9%]; p &lt; 0.001, and 60 [21.1%] <em>vs</em> 17 [6.1%]; p &lt; 0.001). Visepegenatide demonstrated a significant reduction in fasting plasma glucose and 2-h postprandial glucose compared with placebo. Trends in the improvement of these variables were maintained during the open-label extended treatment period. No severe gastrointestinal adverse event or severe hypoglycaemia was reported during the 52-week study period.</div></div><div><h3>Interpretation</h3><div>Once-weekly injection of visepegenatide 150 μg as an add-on treatment to metformin therapy significantly improved glycaemic control and was generally well tolerated in Chinese patients with T2DM who were inadequately controlled with metformin monotherapy.</div></div><div><h3>Funding</h3><div>The study was funded by <span>PegBio Co., Ltd</span>, Suzhou, China.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"51 ","pages":"Article 101197"},"PeriodicalIF":7.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study\",\"authors\":\"Xiaoling Cai ,&nbsp;Linong Ji ,&nbsp;Mingxia Yuan ,&nbsp;Jianhua Ma ,&nbsp;Fang Bian ,&nbsp;Sheli Li ,&nbsp;Wuyan Pang ,&nbsp;Shuang Yan ,&nbsp;Huimin Zhou ,&nbsp;Minghui Hou ,&nbsp;Wenhui Li ,&nbsp;Ying Jia ,&nbsp;Li Liu ,&nbsp;Ke Ding ,&nbsp;Michael Xu\",\"doi\":\"10.1016/j.lanwpc.2024.101197\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Visepegenatide, a once-weekly glucagon-like peptide-1 receptor agonist injection, demonstrated effective glycaemic control and good tolerability without the requirement of dose titration in the two completed phase 2 studies. We aimed to evaluate the efficacy and safety of visepegenatide in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin monotherapy in this phase 3 clinical study.</div></div><div><h3>Methods</h3><div>This multicentre phase 3 clinical study included a 24-week, randomised, placebo-controlled, double-blind period followed by a 28-week open-label extended treatment period. Patients (N = 620) aged ≥18 and ≤75 years with glycated haemoglobin (HbA<sub>1c</sub>) ≥7.0% and ≤10.5% [≥53.0 and ≤91.27 mmol/mol], were randomized in a 1:1 ratio to receive visepegenatide 150-μg or placebo once-weekly subcutaneous injection during the double-blind period. Subsequently, the patients in the placebo group were switched to visepegenatide treatment (placebo→visepegenatide group), and the patients in the visepegenatide group continued the same treatment during the open-label extended treatment period. The primary endpoint was the change in HbA<sub>1c</sub> from baseline to week 24.</div></div><div><h3>Findings</h3><div>At week 24, the placebo-adjusted least squares mean (LSM) change of HbA<sub>1c</sub> was −0.57% (95% CI −0.71 to −0.43) with visepegenatide (p &lt; 0.001). The proportion of patients achieving HbA<sub>1c</sub> &lt; 7.0% and ≤6.5% [&lt;53 and ≤ 48 mmol/mol] was higher in the visepegenatide group versus the placebo group (115 [40.5%] <em>vs</em> 50 [17.9%]; p &lt; 0.001, and 60 [21.1%] <em>vs</em> 17 [6.1%]; p &lt; 0.001). Visepegenatide demonstrated a significant reduction in fasting plasma glucose and 2-h postprandial glucose compared with placebo. Trends in the improvement of these variables were maintained during the open-label extended treatment period. No severe gastrointestinal adverse event or severe hypoglycaemia was reported during the 52-week study period.</div></div><div><h3>Interpretation</h3><div>Once-weekly injection of visepegenatide 150 μg as an add-on treatment to metformin therapy significantly improved glycaemic control and was generally well tolerated in Chinese patients with T2DM who were inadequately controlled with metformin monotherapy.</div></div><div><h3>Funding</h3><div>The study was funded by <span>PegBio Co., Ltd</span>, Suzhou, China.</div></div>\",\"PeriodicalId\":22792,\"journal\":{\"name\":\"The Lancet Regional Health: Western Pacific\",\"volume\":\"51 \",\"pages\":\"Article 101197\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Regional Health: Western Pacific\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666606524001913\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Regional Health: Western Pacific","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666606524001913","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

背景在已完成的两项2期研究中,每周注射一次的胰高血糖素样肽-1受体激动剂维塞那肽显示出有效的血糖控制和良好的耐受性,且无需剂量滴定。这项多中心 3 期临床研究包括 24 周随机、安慰剂对照、双盲期和 28 周开放标签延长治疗期。年龄≥18岁和≤75岁、糖化血红蛋白(HbA1c)≥7.0%和≤10.5%[≥53.0和≤91.27 mmol/mol]的患者(N = 620)按1:1的比例随机分配,在双盲期每周一次皮下注射维塞那肽150微克或安慰剂。随后,安慰剂组患者转为接受维塞庚那肽治疗(安慰剂→维塞庚那肽组),维塞庚那肽组患者在开放标签延长治疗期内继续接受同样的治疗。研究结果第24周时,维塞那肽的安慰剂调整后最小二乘法均值(LSM)变化为-0.57%(95% CI -0.71至-0.43)(p <0.001)。与安慰剂组相比,维塞那肽组达到 HbA1c <7.0%和≤6.5% [<53 和≤48 mmol/mol]的患者比例更高(115 [40.5%] vs 50 [17.9%];p <0.001;60 [21.1%] vs 17 [6.1%];p <0.001)。与安慰剂相比,维塞那肽可显著降低空腹血浆葡萄糖和餐后 2 小时血糖。在开放标签延长治疗期间,这些变量的改善趋势得以保持。在为期52周的研究期间,没有严重胃肠道不良事件或严重低血糖的报道。解释作为二甲双胍治疗的附加疗法,每周注射一次150微克的维培那肽可显著改善二甲双胍单药治疗控制不佳的中国T2DM患者的血糖控制,且耐受性良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study

Background

Visepegenatide, a once-weekly glucagon-like peptide-1 receptor agonist injection, demonstrated effective glycaemic control and good tolerability without the requirement of dose titration in the two completed phase 2 studies. We aimed to evaluate the efficacy and safety of visepegenatide in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin monotherapy in this phase 3 clinical study.

Methods

This multicentre phase 3 clinical study included a 24-week, randomised, placebo-controlled, double-blind period followed by a 28-week open-label extended treatment period. Patients (N = 620) aged ≥18 and ≤75 years with glycated haemoglobin (HbA1c) ≥7.0% and ≤10.5% [≥53.0 and ≤91.27 mmol/mol], were randomized in a 1:1 ratio to receive visepegenatide 150-μg or placebo once-weekly subcutaneous injection during the double-blind period. Subsequently, the patients in the placebo group were switched to visepegenatide treatment (placebo→visepegenatide group), and the patients in the visepegenatide group continued the same treatment during the open-label extended treatment period. The primary endpoint was the change in HbA1c from baseline to week 24.

Findings

At week 24, the placebo-adjusted least squares mean (LSM) change of HbA1c was −0.57% (95% CI −0.71 to −0.43) with visepegenatide (p < 0.001). The proportion of patients achieving HbA1c < 7.0% and ≤6.5% [<53 and ≤ 48 mmol/mol] was higher in the visepegenatide group versus the placebo group (115 [40.5%] vs 50 [17.9%]; p < 0.001, and 60 [21.1%] vs 17 [6.1%]; p < 0.001). Visepegenatide demonstrated a significant reduction in fasting plasma glucose and 2-h postprandial glucose compared with placebo. Trends in the improvement of these variables were maintained during the open-label extended treatment period. No severe gastrointestinal adverse event or severe hypoglycaemia was reported during the 52-week study period.

Interpretation

Once-weekly injection of visepegenatide 150 μg as an add-on treatment to metformin therapy significantly improved glycaemic control and was generally well tolerated in Chinese patients with T2DM who were inadequately controlled with metformin monotherapy.

Funding

The study was funded by PegBio Co., Ltd, Suzhou, China.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
The Lancet Regional Health: Western Pacific
The Lancet Regional Health: Western Pacific Medicine-Pediatrics, Perinatology and Child Health
CiteScore
8.80
自引率
2.80%
发文量
305
审稿时长
11 weeks
期刊介绍: The Lancet Regional Health – Western Pacific, a gold open access journal, is an integral part of The Lancet's global initiative advocating for healthcare quality and access worldwide. It aims to advance clinical practice and health policy in the Western Pacific region, contributing to enhanced health outcomes. The journal publishes high-quality original research shedding light on clinical practice and health policy in the region. It also includes reviews, commentaries, and opinion pieces covering diverse regional health topics, such as infectious diseases, non-communicable diseases, child and adolescent health, maternal and reproductive health, aging health, mental health, the health workforce and systems, and health policy.
期刊最新文献
Socioeconomic disadvantage and polygenic risk of overweight in early and mid-life: a longitudinal population cohort study spanning 12 years A contemporary analysis of the Australian clinical and genetic landscape of spinal muscular atrophy: a registry based study A complex intervention to reduce antibiotic prescribing in rural China: a cluster randomised controlled trial Impact of time to antibiotics on clinical outcome in paediatric febrile neutropenia: a target trial emulation of 1685 episodes Why I decide to leave South Korea healthcare system
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1